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  1 “Keep the home fires burning” was a patriotic British song, popular during the 1914-18 World 
War; it carried the message that homes should be kept warm and welcoming while loved ones were 
away at the war	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ABSTRACT 
Living cells obtain energy either by oxidizing reduced compounds of organic or mineral origin, or 
by absorbing light. Whichever energy source is utilized, some of the energy released is conserved 
by converting adenosine diphosphate (ADP) to adenosine triphosphate (ATP), which are analogous 
to the chemicals in a rechargeable battery. Energy released by conversion of ATP back to ADP is 
used to drive most energy-requiring processes, including cell growth, cell division, communication 
and movement. It is clearly essential to life that the production and consumption of ATP are always 
maintained in balance, and the AMP-activated protein kinase (AMPK) is one of the key cellular 
regulatory systems that ensures this. In eukaryotic cells (cells with nuclei and other internal 
membrane-bound structures, including human cells) most ATP is produced in mitochondria, which 
are thought to have been derived by engulfment of oxidative bacteria by a host cell not previously 
able to utilize molecular oxygen. AMPK is activated by increasing AMP or ADP (AMP being 
generated from ADP whenever ADP rises) coupled with falling ATP. Relatives of AMPK are found 
in essentially all eukaryotes, and it may have evolved to allow the host cell to monitor the output of 
the newly acquired mitochondria and step their ATP production up or down according to demand. 
Structural studies have illuminated how AMPK achieves the task of detecting small changes in 
AMP and ADP, despite the presence of much higher concentrations of ATP. Recently, it has been 
shown that AMPK can also sense the availability of glucose, the primary carbon source for most 
eukaryotic cells, via a mechanism independent of changes in AMP or ADP. Once activated by 
energy imbalance or glucose lack, AMPK modifies many target proteins by transferring phosphate 
groups to them from ATP. By this means, numerous ATP-producing processes are switched on 
(including the production of new mitochondria) and ATP-consuming processes are switched off, 
thus restoring energy homeostasis. Drugs that modulate AMPK have great potential in the treatment 
of metabolic disorders such as obesity and Type 2 diabetes, and even cancer. Indeed, some existing 
drugs such as metformin and aspirin, which were derived from traditional herbal remedies, appear 
to work in part by activating AMPK.
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1. Being alive requires a constant and rechargeable source of energy 
The cell (a term coined by one of the founder members of the Royal Society, Robert Hooke, while 
making microscopic observations of plant material, which he thought looked “much like a 
honeycomb” [1]) is the fundamental unit of all living organisms. There are now believed to be three 
major domains of life: (i) the archaea2, which inhabit extreme environments like hot springs and 
deep ocean vents and (as their name suggests) may be the most ancient life-form; (ii) the bacteria; 
and (iii) the eukarya or eukaryotes. Archaeal and bacterial cells range in diameter from 1-5 µm, and 
have few internal membranes, while eukaryotic cells are larger (typically 10-100 µm), envelop their 
DNA in a membrane-bound nucleus, and contain several other types of substructures bound by lipid 
membranes known as organelles. Although the beautiful multicoloured rings that fringe some hot 
springs are composed of archaea, and bacteria can also form visible colonies, individual living 
organisms that are of dimensions visible to humans are invariably eukaryotic and multicellular, 
often containing complex and highly organized assemblages of cells. An adult human, for example, 
has been estimated to contain >1013 cells [2]. 
 All living cells require a constant supply of energy to grow and reproduce, to repair wear and 
tear, to maintain intracellular compositions often very different from their extracellular 
environment, and to perform other specialized functions such as secretion of materials into their 
surroundings, electrical communication, or movement. They obtain this energy in one of three 
ways: (i) by heterotrophy, as practised by animals, in which organisms and their component cells 
ingest or absorb reduced organic compounds and oxidize them, usually to CO2, by the process 
known as catabolism (hence “keeping the home fires burning”); (ii) by photoautotrophy as in green 
plants, in which the organism uses energy from sunlight to fix and convert CO2 into reduced organic 
compounds; and (iii) by lithoautotrophy in which the organism oxidizes reduced compounds of 
mineral origin. Despite these radically different lifestyles, all cells conserve some of the energy 
released in these processes using a common currency, by converting the nucleotide adenosine 
diphosphate (ADP) and phosphate ions (Pi) into adenosine triphosphate (ATP) (Figure 1A). Under 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  2	  biological	  terms	  in	  italics	  are	  defined	  in	  the	  glossary	  that	  accompanies	  this	  article	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normal conditions, the equilibrium for the reaction that interconverts ATP and ADP + Pi lies well in 
favour of ATP hydrolysis (i.e. towards the left-hand side of Fig. 1A). However, by coupling ATP 
synthesis to oxidation of reduced compounds, or to photosynthesis, most cells maintain ATP 
concentrations around 10-fold higher than those of ADP, which is many orders of magnitude away 
from the equilibrium position of the hydrolysis reaction. A useful analogy can be drawn between 
ATP and ADP and the chemicals in a rechargeable battery: catabolism or photosynthesis “charge up 
the battery” by converting ADP to ATP, while the majority of other cellular functions require 
energy and are mostly driven (directly or indirectly) by being coupled to conversion of ATP back to 
ADP. Clearly, to sustain life this “battery” needs to remain fully charged (ATP:ADP ≈ 10:1), which 
requires that the rate of ATP production by catabolism and/or photosynthesis is exactly balanced by 
the rate at which ATP is consumed by energy-requiring processes, including the biosynthesis of 
macromolecules required for cell growth (anabolism). There is no a priori reason why these two 
complex processes should automatically remain in balance, and the fact that they usually do is 
because cells contain sensitive control systems to preserve that balance. One of the most important 
of these is the AMP-activated protein kinase or AMPK, which forms the main topic of this article. 
 While discussing ATP and ADP, I should also mention the third adenine nucleotide, adenosine 
monophosphate or AMP, which plays an important role in this story. Although produced in a few 
other reactions, the major cellular source of AMP appears to be the reaction catalysed by adenylate 
kinases, enzymes that catalyse the interconversion of the three adenine nucleotides (Fig. 1B). There 
is little change in free energy in this reaction, so it is readily reversible with an equilibrium constant 
close to 1 such that, at equilibrium, [ATP].[AMP]/[ADP]2 will be ≈1. If this reaction is indeed at or 
near equilibrium (which appears to be the case in most eukaryotic cells), and cells maintain an 
ATP:ADP ratio of 10:1 as discussed above, it follows that the ratio of ATP:AMP will be 100:1. In a 
cell with a fully charged “battery”, the concentration of AMP will therefore be 100-fold lower than 
that of ATP and 10-fold lower than that of ADP. However, if the ADP:ATP ratio starts to rise (i.e. 
the “battery is going flat”), and the adenylate kinase reaction is at equilibrium then it is easy to 
show [3] that the AMP:ATP ratio will rise as the square of the ADP:ATP ratio, making the former a 
much more sensitive indicator of falling cellular energy status than the latter. This was realized by 
Sir Hans Krebs as long ago as 1964, who in his Croonian lecture to the Royal Society stated: “it is 
noteworthy that the tissue concentrations of AMP are subject to much greater percentage changes 
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under physiological conditions than the concentrations of ATP or ADP, or the ratio ATP/ADP” [4]. 
These observations help to explain why the AMPK system, a sensor of cellular energy status, 
responds primarily to changes in AMP:ATP ratio rather than ADP:ATP, as will be discussed in 
more detail later. There are also at least three metabolic enzymes that respond to cellular energy 
status independently of AMPK (see Fig. 2): (i) phosphofructokinase (involved in glycolysis, the 
initial pathway of glucose breakdown); (ii) phosphorylase (involved in breakdown of glycogen, the 
storage form of glucose) and (iii) fructose-1,6-bisphosphatase (FBPase), which reverses the 
phosphofructokinase step, albeit using a different reaction, during de novo synthesis of glucose 
(gluconeogenesis) in the liver. Phosphofructokinase and phosphorylase are catabolic enzymes that 
are activated by decreased cellular energy status, while fructose-1,6-bisphosphatase is an anabolic 
enzyme that is inhibited by decreased cellular energy status. It is interesting that, like AMPK, all 
three of these energy-sensing metabolic enzymes respond primarily to AMP and ATP, rather than to 
ADP and ATP [5-7]. 
2. In animal cells, most ATP is generated in mitochondria 
Some of the central metabolic pathways of animal cells are summarized in Fig. 2. The initial 
conversion of glucose to pyruvate, called glycolysis, occurs in the main compartment of the cell 
called the cytoplasm, whereas oxidative metabolism, which uses molecular oxygen to bring about 
complete oxidation of pyruvate (as well as other reduced carbon compounds such as fatty acids) to 
CO2, occurs exclusively in the organelles called mitochondria. Glycolysis is capable of generating 
ATP rapidly, but is inefficient in the sense that only a small amount of ATP is produced for each 
molecule of glucose consumed (just 2 molecules of ATP per molecule of glucose, as opposed to 
>30 by complete oxidation to CO2). 
 The critical event that led to the development of eukaryotic cells (including eventually human 
cells), is now believed to have been an endosymbiosis, i.e. a mutually beneficial engulfment by an 
archaeal host cell of aerobic (oxygen-using) bacteria [8]. The archaeal host may have evolved at a 
time when little oxygen was available in the atmosphere, and was most likely only capable of 
limited catabolism of glucose by glycolysis. By the time of the hypothetical endosymbiotic event, 
the concentration of oxygen in the atmosphere had almost certainly built up to much higher levels 
due to the actions of photosynthetic bacteria, and aerobic bacteria had by then mastered the 
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complex (but energetically rewarding) task of using molecular oxygen to completely oxidize 
reduced carbon compounds to CO2. There was therefore a major potential advantage for the host 
cell to nurture and retain the bacterial invaders, rather than attempting to expel or destroy them as 
might normally occur with a parasite. Since the host and endosymbiont may not initially have been 
able to exchange ATP and ADP (which is now carried out by membrane transporters of the 
ADP/ATP carrier (AAC) family [9]), it has been argued that the early advantage to the host may 
simply have resided in the ability of the endosymbiont to reduce the intracellular concentration of 
oxygen, whose rising levels might otherwise have been becoming toxic [10]). However, once ATP 
and ADP could be exchanged across the membrane of the endosymbiont, the benefit to the host cell 
would have been greatly enhanced. In return, the enveloped bacterium would have found a much 
richer source of carbon nutrients than would be the case outside of the host cell. So mutually 
advantageous was this happy arrangement that it is thought that the bacteria quite quickly became 
completely integrated into the host cell, and became what we now call mitochondria (Fig. 3). 
Although this endosymbiotic origin of mitochondria was controversial when first proposed by Lynn 
Margulis (formerly Lynn Sagan) in 1967 [8], the evidence in its favour is now rather overwhelming. 
For example, analysis of amino acid sequences shows that many mitochondrial proteins are closely 
related to their bacterial counterparts, whereas cytoplasmic proteins tend to be more similar to their 
archaeal relatives [11]. In addition, mitochondria still contain their own DNA that replicates 
independently of the DNA in the nucleus, as well as machinery for synthesizing the RNAs and 
proteins encoded by that DNA. Despite this, the majority of the genes that were acquired from the 
bacterium during the endosymbiotic event have, for reasons that are not completely clear, been 
transferred into nuclear DNA, so that mitochondria are now quite incapable of living freely on their 
own. Note that despite the oval “bacterium-like” appearance of mitochondria in transmission 
electron micrographs (Fig. 3A), this is a rather misleading impression caused by the cutting of thin 
sections prior to electron microscopy. Mitochondria often occur in cells as elongated and even 
branched tubular networks (Fig. 3B), as well as in more fragmented, vesicular forms; these alternate 
forms exist in a dynamic equilibrium mediated by fission and fusion, and which predominates is 
dependent upon conditions. 
 By a similar (although probably much later) endosymbiotic process, photosynthetic eukaryotes 
such as green plants are thought to have arisen when a host eukaryotic cell (which probably already 
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contained mitochondria) engulfed blue-green algae, a type of photoautotropic bacterium, which 
then became chloroplasts. This relationship between blue-green algae and chloroplasts is more 
obvious than that between mitochondria and aerobic bacteria, and consequently was proposed much 
earlier, by the Russian biologist Constantin Mereschkowsky in 1905 [12]. This event allowed plants 
to convert ADP to ATP using energy from sunlight, and to fix and reduce carbon dioxide to 
generate glucose that could then be stored in the form of the polysaccharide starch, still one of the 
major sources of food for humans. Plant cells also contain mitochondria, and when the light fades at 
night they break down starch stored during the day into glucose, to fuel ATP production by their 
mitochondria. Cells in the subterranean parts of the plant (the roots) use mitochondria for ATP 
production even during the day. 
 Like the bacteria and blue-green algae from which they are thought to derive, mitochondria (Fig. 
3A) and chloroplasts are surrounded by double membranes. Embedded in their inner membranes 
are chains of redox-active proteins and lipids (called the respiratory chain in mitochondria, and 
photosystems in chloroplasts). These transfer electrons down energy gradients, with the electrons 
that have passed down the mitochondrial respiratory chain eventually being used to reduce oxygen 
and H+ ions (protons) to water. Some of the energy released during electron transfer down these 
chains is conserved by pumping protons from the inner compartments of the mitochondrion (or 
chloroplast) to the outside. This creates a gradient of electrical charge, as well as a chemical 
gradient of protons across the inner membrane, representing yet another store of energy. Although 
these gradients can be used to directly drive some energy-requiring processes in the organelles 
themselves, they are mainly dissipated by remarkable multisubunit protein machines known as ATP 
synthases or F1Fo ATPases [13]. These contain Fo sub-complexes embedded in the inner membrane, 
which rotate within the membrane as protons pass back through them, requiring 10-15 protons to 
pass for every 360o rotation. This rotation is then transmitted via a central stalk to the F1 sub-
complex located on the inside of the inner membrane, which contains the ATP synthase enzyme 
that generates 3 molecules of ATP from ADP and Pi for every rotation (the system can also operate 
in reverse, using energy from ATP hydrolysis to pump protons out). As already mentioned, 
mitochondria can generate around 36 molecules of ATP per molecule of glucose by this process, as 
opposed to the two generated by the more limited pathway of glycolysis in the cytoplasm. 
Mitochondria and chloroplasts can also export ATP into the cytoplasm by means of ATP/ADP 
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carriers that exchange ADP for ATP across their inner membranes. Mitochondria therefore 
generate the majority of the ATP in most animal cells. 
 A defining feature of mitochondria is that their inner membranes are greatly invaginated, 
containing infoldings called cristae (Fig. 3A). This greatly increases the surface area of membrane 
that can be occupied by the respiratory chains or photosystems, as well as by the ATP synthases, 
thus enhancing the production of ATP per unit volume. It has been argued [14] that the acquisition 
of mitochondria in the early eukaryote may have allowed the large increase in cell size that 
subsequently occurred, because it meant that ATP could now be generated throughout the volume 
of the cell, rather than just close to the plasma membrane where it occurs in bacterial or archaeal 
cells, perhaps placing a limit on the ultimate size of the latter. This innovation may also have 
allowed the proliferation of other membrane-bound organelles, such as the nucleus, endoplasmic 
reticulum, Golgi apparatus, endosomes and lysosomes, as well as processes involving membrane 
traffic such as exocytosis and endocytosis (fusion of intracellular lipid vesicles with the plasma 
membrane, thus delivering materials to the exterior, and vice versa). These processes, as well as 
others such as bodily movement by skeletal muscles in animals, and the electrical communication 
that is required to control it, are particularly expensive in terms of energy turnover, and none of 
them are found in bacteria. Such innovations may ultimately have allowed the development of more 
complex multicellular organisms such as humans, which may not have been possible using archaeal 
or bacterial cells because they have to utilize energy with such great efficiency. 
 When the endosymbiotic engulfment of aerobic bacteria first occurred to generate what we now 
know as mitochondria, one can envisage that the host cell would have needed to develop a system 
that could monitor the primary output of the endosymbiont, i.e. ATP, and signal back for it to step 
ATP production up or down according to demand. The AMP-activated protein kinase (AMPK), the 
main topic of this review, monitors the energy status of cells by sensing the relative levels of AMP, 
ADP and ATP, as discussed below. When it is switched on as cellular energy status falls, one of the 
things it does is to promote the production of new mitochondria, as well as assisting with the 
disposal of old, damaged regions of the mitochondrial network and recycling their contents (see 
Section 6.2). I would therefore argue that, following the endosymbiosis event that created 
mitochondria, AMPK may have evolved to provide the critical regulatory link between the new 
endosymbiont and its host. 
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3. Protein kinases and phosphatases act as molecular switches 
 As its name suggests, AMPK is a protein kinase, an enzyme that catalyses protein 
phosphorylation, the transfer of the terminal phosphate group of ATP onto an amino acid side chain 
of a target protein carrying a hydroxyl group, thus creating a phosphate ester (Fig. 4). Of the 20 
commonly occurring amino acids that make up proteins, only serine, threonine or tyrosine carry 
hydroxyl groups, and individual protein kinases tend to be specific either for the aliphatic side 
chains of serine or threonine (like AMPK), or for the aromatic side chain of tyrosine. Protein 
phosphorylation is reversed by enzymes called protein phosphatases, which catalyse the hydrolysis 
of the phosphate ester to regenerate the unmodified target protein. Note that protein kinases and 
phosphatases catalyse distinct reactions (Fig. 4), each of which are essentially irreversible under 
cellular conditions (the high ATP:ADP ratio in cells drives kinase reactions to completion, while 
the high concentration of cellular water drives protein phosphatase reactions to completion). This 
means that a kinase-phosphatase cycle acts as a molecular switch, reversibly switching the target 
protein between the dephosphorylated and phosphorylated states according to the relative catalytic 
activities of the kinase and phosphatase. Creation of a phosphate ester adds two negative charges to 
an amino acid side chain that was previously uncharged (Fig. 4), and this can have profound effects 
on the function of the target protein. For example, if the target protein is an enzyme it can switch its 
catalytic activity on or off; in other cases it may trigger a protein:protein interaction that 
subsequently alters the subcellular location of the protein or targets it for degradation. Cells also 
contain other molecular switch mechanisms, including GTP-binding proteins (G proteins), which 
are switched between GDP-bound and GTP-bound forms by upstream modifying proteins called 
guanine nucleotide exchange factors (GEFs) and GTPase activator proteins (GAPs). Protein 
kinase:phosphatase cycles and G protein GEF:GAP cycles can therefore act as molecular switches 
(although only acting as truly digital, “on-off” switches under certain conditions [15, 16]) and are 
thus analogous to the transistors in an electronic circuit. Indeed, the analogy can be taken further, 
because there are >500 protein kinases, >100 protein phosphatases, and >100 G proteins encoded in 
the human genome (not counting regulatory subunits). Because protein kinase/phosphatase pairs 
often regulate the activity of other protein kinases and phosphatases, with the help of G proteins and 
additional molecular switch mechanisms they form complex networks of signalling pathways 
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within the cell, analogous to the central processor unit (CPU) of a computer. Just as in a computer, 
these signalling networks receive input information via receptors and sensor proteins (one example 
of which is AMPK itself). The signalling network then processes the information to convert it into 
appropriate output, which takes the form of changes in either the function or the quantity of 
downstream target proteins. The ultimate downstream targets include enzymes and other proteins 
involved in metabolism, cell growth and division, movement, secretion and so on. 
4. Structure, occurrence and regulation of AMPK 
4.1 AMPK is expressed in almost all eukaryotes 
AMP-activated protein kinase (AMPK) exists universally as complexes of three different protein 
subunits (heterotrimers) comprising a catalytic α subunit that carries the protein kinase activity, and 
regulatory β and γ subunits. Each of these subunits has a characteristic pattern of amino acids and, 
even though random mutations have meant that the sequences have diverged between different 
species, computer algorithms are available that allow these patterns to be recognized. The 
development of DNA sequencing technology means that we now have almost complete genomic 
DNA sequences for many different organisms, and one can confidently state that, with some 
interesting exceptions discussed in Section 4.2, all eukaryotic genomes, whether from protozoa, 
fungi, plants or animals, contain genes encoding the α, β and γ subunits of AMPK. This fits with 
the proposal, mentioned in Section 2, that AMPK evolved relatively soon after the endosymbiotic 
event that led to the development of eukaryotes. 
4.2 Eukaryotes that lack AMPK – intracellular parasites 
There are a small number of eukaryotes that lack genes encoding AMPK subunits. One is the 
microsporidian parasite Encephalitozoon cuniculi, which is derived from fungi and can infect 
mammalian cells, including cells of immunocompromised humans with AIDS. E. cuniculi has the 
smallest known genome of any eukaryote, encoding only 29 conventional protein kinases (as 
opposed to >500 in humans) and lacks genes encoding AMPK subunits [17]. It is an obligate 
intracellular parasite and has no free-living form other than metabolically inert spores. Although its 
genome does encode glycolytic enzymes, it lacks functional mitochondria producing ATP, although 
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there is good evidence that it has lost these rather than never having had them [18, 19]. Intriguingly, 
E. cuniculi has genes encoding ATP/ADP carriers, which in other eukaryotes are used to export 
ATP from mitochondria and chloroplasts in exchange for ADP, but in E. cuniculi these proteins are 
located in the outer cell membrane [20]. Thus, this organism may be able to survive without AMPK 
because it “steals” ATP from its eukaryotic host cell, which will contain AMPK to maintain energy 
balance on behalf of the parasite. 
 Other examples of eukaryotes lacking AMPK [21] are also parasites that primarily live inside 
other eukaryotic cells. They include Plasmodium falciparum and P. berghei, the causative agents of 
malaria in humans and rodents respectively. Interestingly, two closely related species, P. 
gallinaceum and P. relictum, which cause malaria in birds, do have genes encoding AMPK subunits 
[22], which suggests that the human and rodent parasites have lost genes encoding AMPK relatively 
recently. Like E. cuniculi, malaria parasites spend a large part of their life cycle reproducing inside 
other eukaryotic cells (red blood cells), and may have been able to dispense with AMPK because 
their host cells provides it anyway. Thus, these parasites can be regarded as the exceptions that 
“prove the rule” that AMPK is universal within eukaryotic cells. 
4.3 Multiple forms of AMPK arose by whole genome duplication 
During the evolution of the vertebrates (animals with backbones), it is now thought that two 
successive rounds of duplication of the whole genome occurred [23]. Evidence in favour of this 
hypothesis includes the genome sequence of the marine chordate Amphioxus (Branchiostoma 
floridae), which is believed to have diverged from the vertebrate lineage just prior to these events, 
and where most genes are present as single copies [24]. Two whole genome duplications would 
initially have led to there being four copies of every gene, but since most of these would have been 
redundant in function, in most cases three were lost by subsequent mutations, and their function is 
now often encoded by a single gene once again. However, about 20-30% of genes in the human 
genome have retained two, three or even four copies as a vestige of these gene duplication events. 
Such closely related genes within a single genome are known as paralogues or, if it is clear that 
they have arisen from the two rounds of whole genome duplication that occurred during vertebrate 
development, as 2R-ohnologues (honouring Susumu Ohno, the Japanese scientist who first 
proposed the whole genome duplication hypothesis [23]). Intriguingly, the 20-30% of genes that 
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have retained 2R-ohnologues are highly enriched in proteins involved in cell signalling and 
regulation [25, 26]. Once formed, the 2R-ohnologues could have accumulated mutations and slowly 
diverged in sequence, regulation and tissue distribution, and it has been argued that this allowed 
variations in regulatory behaviour to have appeared in different tissues expressing different 2R-
ohnologues. This increased diversity could then have contributed to the development of the 
complex variety of tissues and organs that exist in vertebrates. 
 The AMPK heterotrimer is a good example of this principle, because in humans there are two 
genes encoding the α subunit (generating α1 and α2 isoforms), two encoding the β subunit 
(generating β1 and β2 isoforms) and three encoding the γ subunit (generating γ1, γ2 and γ3 
isoforms). There is strong circumstantial evidence that these are all 2R-ohnologues [27]. The seven 
genes can combine to form up to twelve heterotrimeric combinations, which show variations in 
their tissue distribution, regulatory properties and subcellular locations [27, 28]. 
4.4 Mechanism of energy-sensing by AMPK 
As mentioned in Section 3, protein kinases often phosphorylate and activate other protein kinases, 
forming chains of protein kinases known as protein kinase cascades. AMPK is no exception to this, 
and is only significantly active after it has been phosphorylated at a specific threonine residue 
within the region of the α subunit that carries the protein kinase activity, usually referred to as 
Thr172 due to its position in the sequences of the α1 and α2 subunits from the rat [29]. This is 
catalysed by two distinct upstream kinases, one called LKB1 [30-32] and the other CaMKK2 [33-
35], potentially enabling AMPK to assimilate input information from two converging upstream 
signalling pathways. Thus, CaMKK2 is activated by increases in intracellular Ca2+ ion 
concentrations, which occurs in response to many hormones acting on cells (Fig. 5, see Section 
4.8). By contrast, LKB1 appears to be constantly active, but forms a key part of the mechanism by 
which AMPK is able to sense the energy status of the cell, which will now be described. 
 As discussed in Section 1, cells normally maintain their ATP:ADP ratio at about 10:1, 
representing a fully charged “battery”. If the rate at which ATP is consumed by energy-requiring 
processes exceeds the rate at which it can be regenerated by catabolism or photosynthesis, the 
ADP:ATP ratio will rise. It might be thought that a system that monitored the cellular energy state 
would sense the ADP:ATP ratio but, as discussed in Section 1, changes in AMP:ATP ratios are 
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generally much larger than those in ADP:ATP. It is therefore interesting that AMPK primarily 
monitors AMP:ATP, although it does also appear to be able to detect changes in ADP:ATP. AMP 
binding causes activation of AMPK by three complementary mechanisms, all of which are 
antagonized by ATP (Fig. 5): (1) increasing the rate at which LKB1 phosphorylates Thr172; (2) 
decreasing the rate at which protein phosphatases dephosphorylate Thr172; and (3) increasing the 
activity of AMPK already phosphorylated on Thr172 (allosteric activation). This tripartite 
activation mechanism makes the system very sensitive to small changes in the cellular AMP:ATP 
ratio [36]. Note that all three effects appear to be due to binding of AMP to AMPK itself, rather 
than to the upstream kinase or phosphatase. Since net Thr172 phosphorylation [the summation of 
mechanisms (1) and (2)] increases the kinase activity of AMPK by >100-fold, while allosteric 
activation [mechanism (3)] increases the kinase activity by a further 10-fold, AMP binding can 
theoretically increase the activity by >1000-fold overall. In practice, however, AMPK activity in 
living cells under physiological conditions probably normally varies over quite a narrow range [37]. 
Because binding of ADP to AMPK can mimic (albeit only at almost 10-fold higher concentrations 
than AMP [37]) mechanisms (1) and (2), but not (3), increases in ADP:ATP ratio would also be 
detected. 
4.5 Structure of the AMPK heterotrimer 
Structures for three almost complete AMPK heterotrimers, i.e. α1β1γ1, α1β2γ1 and α2β1γ1, have 
now been obtained through analysis of X-ray diffraction by crystals. The three structures are quite 
similar; all have AMP bound and with Thr172 in the phosphorylated state [38-40]. They point to the 
fact that AMPK is a remarkable molecular machine for converting changes in adenine nucleotide 
ratios into changes in protein kinase activity. Usually, different functions within proteins are carried 
out by discretely folded regions called domains. The top half of Fig. 6 shows two schematic views 
(derived from crystal structures) of the approximate domain dispositions of one AMPK 
heterotrimer; the two views being rotated 70o around the vertical axis with respect to each other. 
The kinase activity is carried by the kinase domain at the N-terminal end of the α subunit; as in 
other protein kinases, the kinase domain consists of a small N-terminal lobe (N-lobe, yellow in Fig. 
6) and a larger C-terminal lobe (C-lobe, in blue). One of the substrates for the kinase activity, ATP, 
binds (as an Mg.ATP2- complex) in the catalytic site, a deep cleft between these two lobes, while 
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the other, the target protein that is to be phosphorylated, binds partly in a groove on the surface of 
the C-lobe (the target protein binding groove, Fig. 6, top left), and partly in the cleft formed 
between the N- and C-lobes when they close around ATP (see Section 6.1 below for more details of 
this binding site). Phosphorylation of Thr172 by upstream kinases causes a local rearrangement that 
completes the binding site for the target protein. This binding mode brings the serine or threonine 
residue of the target protein adjacent to the terminal phosphate group of ATP, ready for transfer 
[41]. 
 The kinase domain on the AMPK-α subunit is followed by an auto-inhibitory domain (AID, 
orange in Fig. 6) that, in other partial structures, binds to the N- and C-lobes of the kinase domain 
(see Fig. 6, lower right), clamping them in a conformation (a specific folded state) that is much less 
active in catalysis. However, in the complete structures with the activator AMP bound, the AID has 
rotated away from the N-lobe, and interacts between the C-lobe and the γ subunit instead (Fig. 6, 
top right), with the kinase domain now in an active conformation. 
 Following the AID on the α subunit is a region of flexible polypeptide called the α-linker, which 
connects the AID to the C-terminal domain (in red in Fig. 6). The latter interacts with the C-
terminal domain of the β subunit (β-CTD, green), which in turn interacts with the γ subunit, thus 
forming the core of the heterotrimeric complex. The β subunit also contains a carbohydrate-binding 
module (β-CBM, the green domain at the top of the views in Fig. 6) that causes a portion of AMPK 
to bind to glycogen particles in cells. The function of this remains unclear, although it has been 
speculated that AMPK may be able to sense the status of stores of glycogen, which is the major 
cellular reserve of glucose in animal cells [42]. 
 Turning now to the γ subunits, when their amino acid sequences were first determined it was 
realized that they contained patterns of amino acid sequence, termed CBS motifs, that are repeated 
four times, one after the other [43]. These four tandem repeats (CBS1-CBS4) come together in a 
pseudo-symmetrical manner to form the four quadrants of a disc-shaped structure, generating four 
clefts in the centre with a narrow aqueous tunnel between them (Fig. 5). These clefts form the 
binding sites for the regulatory adenine nucleotides AMP, ADP and ATP, although only three are 
actually used. The critical site appears to be that formed by CBS3. Consistent with this, the α-linker 
binds to the surface of the γ subunit containing the CBS3 site when AMP is bound (Fig. 6, top). The 
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α-linker appears to play an important role in the changes in shape that activate the kinase, as 
discussed in the next section. 
4.6 Conformational changes upon AMP binding to AMPK 
Unfortunately, there are no complete crystal structures with ATP bound at the CBS3 site, so we do 
not know the exact changes in conformation (shape) of the complex that occur when ATP replaces 
AMP at that site. However, there is evidence from small angle X-ray scattering in solution [44], and 
from luminescence energy transfer between probes located on the α and γ subunits [39], that the 
heterotrimer adopts a more compact conformation on AMP binding, and conversely that the α and γ 
subunits move apart when ATP is bound. The α-linker can be envisaged as a flexible hinge 
connecting two rather distinct regions of the heterotrimer: (i) the catalytic module, containing the 
carbohydrate-binding module of the β subunit and the kinase domain and AID of the α subunit; and 
(ii) the nucleotide-binding module, containing the γ subunit and the C-terminal domains of the α 
and β subunits (Fig. 6). The displacement of the α-linker from the CBS3 site when ATP binds is 
thought to allow these two modules to move apart [45], thus causing two effects: (i) it allows the 
AID to rotate back into its inhibitory position behind the kinase domain; (ii) it exposes the 
phosphate group on Thr172, which in the AMP-bound structure is buried in a narrow cleft between 
the two modules, to dephosphorylation by protein phosphatases. This proposed change in 
conformation on binding of ATP rather than AMP at the CBS3 site, as depicted rather speculatively 
in the bottom panel of Fig. 6, would therefore explain mechanisms (2) and (3) (see Section 4.4) by 
which AMP binding causes activation of AMPK. 
 If CBS3 is the critical site where the activator AMP binds in competition with the inhibitor ATP, 
what is the purpose of the other two (CBS1 and CBS4)? Although we do not have a complete 
answer, what is clear is that the phosphate groups of the three bound nucleotides come close 
together in the aqueous tunnel in the centre of the γ subunit, where some amino acid side chains 
bind phosphate groups of the nucleotide in more than one site. The three sites thus interact, and it 
has been suggested that the presence of adenine nucleotides in the other two sites alters the shape of 
the CBS3 site such that it binds AMP with almost 10-fold higher affinity than ATP [46]. This 
explains how the γ subunit is able to sense small changes in AMP even in the presence of 100-fold 
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higher concentrations of ATP, which could potentially be envisaged as a difficult task given the 
chemical similarities of the two nucleotides (Fig. 1B). 
4.7 The ADaM site, salicylate and aspirin 
The cleft between the β-CBM and the kinase domain N-lobe forms the binding site for another 
interesting class of AMPK activator. Most of these are synthetic compounds developed in high-
throughput screens by pharmaceutical companies (see Section 6.4). However, many people believe 
that these drugs are mimicking a naturally occurring metabolite that binds in the same site, which is 
why it is referred to as the Allosteric Drug and Metabolite (ADaM) site (Fig. 6, top left) [47]. One 
natural product that does bind to the ADaM site and activates AMPK, although it only occurs 
naturally in plants, is salicylate [48]. Salicylate is a hormone released by regions of plants that have 
been infected by pathogens, which triggers a defense response in uninfected regions [49]. The bark 
of white willow (Salix alba), from which the name salicylate is derived, is a rich source of salicin, a 
glucosyl derivative of salicylate. Extracts of willow bark were used in the 18th century by the 
Reverend Edward Stone to treat himself and his parishioners of “agues” (fevers), resulting in a 
paper read before the Royal Society in 1763 [50]. He was in fact rediscovering a remedy that had 
been known in ancient times, and that was described in Sumerian stone tablets and Egyptian 
papyrus documents dating from the 3rd millennium BCE [51]. Salicin was also successfully tested 
for treatment of rheumatic fever by Dr. Thomas Maclagan at the Royal Infirmary in my home town 
of Dundee in the 1870s [52], and because he left some patients untreated this is sometimes regarded 
as one of the first controlled clinical trials. However, the use of salicylates really took off when 
Bayer introduced the synthetic derivative acetyl salicylate (aspirin) in 1899 [51]. In 1971 Sir John 
Vane discovered that aspirin irreversibly inhibited cyclo-oxygenase, the key enzyme of biosynthesis 
of lipid mediators such as prostaglandins and thromboxane, with the latter promoting platelet 
aggregation and hence blood clotting [53]. However, once it enters the bloodstream aspirin is 
rapidly broken down to salicylate with a half-life of just a few minutes, while the resulting 
salicylate is stable for many hours [54]. Moreover, while the anti-blood clotting effects of aspirin 
are undoubtedly mediated by inhibition of thromboxane synthesis, it remains uncertain whether 
inhibition of cyclo-oxygenase explains all of the other effects of aspirin. Indeed, it has been 
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suggested that some of its anti-inflammatory [55] and even pain-relieving effects [56] might be 
mediated instead by AMPK activation. 
4.8 The CaMKK2 pathway and effects of hormones on AMPK 
Like LKB1, CaMKK2 can activate AMPK by phosphorylating Thr172 on the AMPK-α subunit 
[33-35], and it is itself activated by interaction with the Ca2+-bound form of the small Ca2+-binding 
protein calmodulin. Many hormones, which act via receptors that either activate G proteins or 
protein-tyrosine kinases, cause release from the cell membrane of the second messenger, inositol 
trisphosphate, which in turn releases Ca2+ from intracellular storage sites. Such hormones therefore 
activate AMPK via the CaMKK2 pathway. This includes two hormones or mediators that act on the 
endothelial cells that line blood vessels [57], i.e. thrombin and vascular endothelial cell growth 
factor (VEGF) [58, 59]. Thrombin is produced from its inactive precursor prothrombin as one of the 
final steps in the blood-clotting cascade, whereas VEGF is released by cells that are hypoxic (short 
of oxygen) and promotes the growth of new blood vessels (angiogenesis). Indeed, there is evidence 
that the α1 isoform of AMPK is required for angiogenesis induced by VEGF [59]. 
 The Ca2+-CaMKK2 pathway for activation of AMPK is also involved in the response of 
neurones (nerve cells) that trigger sensations of hunger and hence promote feeding behavior; these 
are located in the hypothalamus, the small brain region that links the nervous system and the 
endocrine (hormonal) system. Hormones that trigger activation of AMPK via CaMKK2 in the 
hypothalamus include ghrelin [60, 61], which is released from the stomach during fasting. It is 
thought to act on neurones immediately upstream of other neurones that express agouti-related 
protein (AGRP), which trigger feeding behavior when they are excited.  There is also evidence that 
AMPK activation in these upstream neurones triggers a positive feedback mechanism that ensures 
that they remain active even after ghrelin release has ceased. If this is correct, AMPK in these 
neurons will only be switched off when “satiety” signals act upon them; these are most likely to be 
opioid peptides, released in response to “satiety” hormones such as leptin [60] from other neurones 
that express the opioid precursor protein, pro-opiomelanocortin (POMC). Consistent with the role 
of CaMKK2 in the response to ghrelin, acute inhibition of CaMKK2 by direct injection of an 
inhibitor into the hypothalamus of normal mice led to reduced food intake and weight loss, while 
mice with a genetic knockout of CaMKK2 consumed less and were resistant to weight gain induced 
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by an energy-rich diet [62]. As discussed in Section 5, the ancestral role of AMPK may have been 
in the sensing of nutrients, especially glucose. It is therefore intriguing that this ancient nutrient-
sensing system has been co-opted in mammals to control a complex behavioral response, i.e. 
feeding. While AMPK in the hypothalamus appears to be mainly controlled by hormones such as 
ghrelin and leptin released from elsewhere in the body, some neurones in the hypothalamus also 
respond directly to deficiency of glucose in an AMPK-dependent manner [63]. I discuss the 
mechanism of glucose-sensing by AMPK in other cell types in the next Section. 
5. Sensing of glucose by AMPK 
5.1 Glucose sensing may be an ancient role of the AMPK system 
It has been known for many years that the version of AMPK found in brewer’s or baker’s yeast (a 
fungus that can be grown in a unicellular form) is required for responses to glucose starvation [64], 
a stress that activates the kinase [65] by phosphorylation of the threonine residue equivalent to 
Th172 [66]. Evidence that the version of AMPK found in plants also responds to starvation for 
carbohydrate came from studies of the moss Physcomitrella patens; plants deficient in the genes 
encoding AMPK grew normally if the light was kept on constantly, but failed to grow when the 
plants were maintained in a more physiologically relevant 12 hour light:12 hour dark cycle [67]. 
Green plants make hexose sugars from CO2 in their chloroplasts when the light is switched on, so a 
period of darkness is the equivalent of starvation for glucose. Taken together, these findings suggest 
that the response to glucose starvation may have been an ancient function of AMPK in the common 
evolutionary ancestor of fungi, plants and animals. 
 In mammals, the sensing of cellular energy status, by the mechanisms described in Sections 4.4 
to 4.6, has always been regarded as the classical or “canonical” role of AMPK. Although it has been 
known for many years that starving cells of glucose activates AMPK [68], it was generally assumed 
that this was because this manipulation reduced the production of ATP by glucose catabolism, and 
thus increased cellular AMP and ADP. However, it has recently become clear that AMPK can sense 
glucose by a non-canonical mechanism that does not necessarily involve changes in cellular adenine 
nucleotide concentrations. In mouse cells grown in culture, reducing the concentration of glucose in 
the medium caused an activation of AMPK that correlated with increased phosphorylation of 
Thr172, which was not accompanied by any increases in AMP:ATP or ADP:ATP ratios as long as 
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an alternative carbon source was still present [69]. A similar process also occurred under more 
physiological conditions in living animals, since overnight starvation of mice, which caused blood 
glucose to drop from 9 to 3 mM, was associated with increased Thr172 phosphorylation of AMPK 
within the liver, without any changes in adenine nucleotides. In other cell types, including some 
human cells in culture, there were small increases in AMP:ATP and ADP:ATP ratios when glucose 
was removed from the medium, possibly because these cells are more dependent upon the more 
glucose-hungry glycolytic pathway for their ATP production. Nevertheless, glucose starvation still 
activated AMPK in these cells, albeit to a smaller extent, when they expressed an AMPK mutant in 
which binding of AMP at the critical CBS3 site on the γ subunit was ablated, thus preventing the 
response to agents that increase intracellular AMP [70]. Thus, even in cells where removal of 
glucose from the medium does cause some decrease in energy status, there is an AMP/ADP-
independent component to the mechanism by which glucose lack is sensed. 
5.2 Mechanism of glucose sensing by AMPK 
How does mammalian AMPK sense glucose, assuming that it is not by sensing changes in AMP, 
ADP and ATP? One initial clue came from findings that the β1 and β2 subunits of AMPK are 
modified at their N-termini by covalent modification using the C14 fatty acid, myristic acid [71, 
72]. This modification, N-myristoylation, occurs in other proteins and often causes the modified 
protein to attach to membranes, with the hydrophobic myristoyl group being buried in one layer of 
the double layer of phospholipids (the phospholipid bilayer) in all membranes. Myristoylation of 
the β1 subunit was found to be necessary for increased Thr172 phosphorylation in response to 
glucose deprivation, and also for AMPK to cluster at an unidentified membrane location near the 
nucleus in response to glucose deprivation [72]. 
 The next clue came from studies of the protein Axin, a scaffold protein previously known for its 
role in another signaling pathway (Wnt signaling). Knockdown of Axin expression caused 
accumulation in mouse liver of fatty acids in the form of triacylglycerols, especially after overnight 
starvation [73]. This was reminiscent of what might be expected for reduced activation of AMPK, 
since when AMPK is activated it reduces fat storage by inhibiting fat synthesis and promoting fat 
oxidation (see Section 6.2). AMPK activation after overnight starvation was indeed reduced by 
Axin knockdown. It was subsequently shown that Axin forms a binary complex with the upstream 
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kinase for AMPK, LKB1, and that AMP then promotes the formation of a ternary complex 
involving Axin, LKB1 and AMPK. Axin is therefore an adapter protein that promotes the 
phosphorylation and activation of AMPK by LKB1 by bringing the upstream and downstream 
kinases together in a complex. This effect was promoted by AMP, thus explaining mechanism (1) 
of the tripartite mechanism for activation of AMPK by AMP, already discussed in Section 4.4. 
 The missing link between membrane association, Axin and glucose sensing was identified from 
a screen that searched for other proteins interacting with Axin, which yielded the protein p18 (also 
known as Lamtor1) [74]. p18/Lamtor1 is a resident protein of lysosomes, another organelle that is 
specific to eukaryotes, which occur in plant and fungal cells as larger structures called vacuoles. 
The interior of lysosomes or vacuoles are maintained at a lower pH than the cytoplasm due to 
pumping of protons into the interior by a rotary pump driven by ATP hydrolysis (the vacuolar 
ATPase or v-ATPase), which is related to the F1Fo ATPase that synthesizes ATP in the 
mitochondria (see Section 2). Lysosomes contain degradative enzymes that are active at this low pH 
and that break down proteins, lipids and polysaccharides. The latter are delivered to lysosomes by 
membrane trafficking events such as autophagy (which delivers intracellular materials) and 
endocytosis (which delivers extracellular materials), thus enabling recycling of their components. 
p18/Lamtor1 is a component of the pentameric Ragulator complex, which is resident on the 
lysosome partly because of N-terminal modifications of p18/Lamtor1 by the C14 and C16 fatty 
acids myristic and palmitic acid [75] (recall that the β subunits of AMPK are also subject to N-
terminal myristoylation), and partly because it interacts with the v-ATPase [76]. 
 Further analysis of these interactions showed that, upon starving cells for glucose, a multiprotein 
complex involving the v-ATPase, Ragulator, LKB1 and AMPK was formed on the cytoplasmic 
surface of lysosomes; since each component of this complex itself contains multiple subunits (at 
least 14, 5, 3 and 3 respectively) we refer to this as a super-complex, or more specifically as the 
Axin-based AMPK activation complex. 
5.3 What is being sensed, and what is the sensor? 
These findings still did not reveal how glucose was being sensed. One key question was whether it 
was glucose itself that was recognized, or a product of its metabolism. By systematically knocking 
down expression of enzymes of glycolysis and the pentose phosphate pathway (two of the major 
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pathways for the initial metabolism of glucose, see Fig. 2), it became clear that repression of AMPK 
activation by glucose required its metabolism at least through the first three steps of glycolysis, i.e. 
as far as fructose-1,6-bisphosphate (FBP). That it was FBP itself that was being sensed came from 
experiments showing that of all ten intermediates of the glycolytic pathway, only FBP caused 
dissociation of the Axin-based AMPK activation complex present in a sub-cellular fraction 
containing lysosomal membranes, isolated from glucose-starved cells. 
 If FBP is being sensed, what is the sensor? One possibility was that aldolase, the enzyme that 
metabolizes FBP in the glycolytic pathway (Fig. 2), might be “moon-lighting” as a sensor. 
Consistent with this idea, knockdown of aldolase expression led to AMPK activation even in cells 
incubated in high glucose [69]. However, since knockdown would affect not only the putative 
glucose-sensing role of aldolase but also its metabolic role, alternative approaches were required. 
More convincing results came from studies with a previously described mutant of aldolase (D34S), 
which still binds FBP with normal affinity even though the maximal catalytic rate (kcat) is reduced 
by 3 to 4 orders of magnitude [77]. This mutant would therefore be expected to have FBP bound 
even when the overall flux of glycolysis was low due to lack of glucose. Consistent with the model, 
AMPK was no longer activated by glucose starvation in cells expressing this mutant [69]. These 
results suggest that it is aldolase that is unoccupied by FBP that signals reduced availability of 
glucose, and that activates AMPK. 
 Intriguingly, aldolase had previously been shown to interact with the lysosomal v-ATPase in 
both yeast and mammalian cells, and even to be required for the correct assembly of the v-ATPase 
complex [78-80]. Even more interestingly, the association between aldolase and FBP in yeast was 
reported to increase dramatically when glucose was present in the medium, which led to the 
proposal that aldolase was a sensor of glucose availability, albeit at that time only thought to be 
involved in regulation of the v-ATPase [79]. Taken together, these findings led to the model shown 
in Fig. 7.  When glucose is available and the flux through glycolysis is therefore high, aldolase that 
is bound to the v-ATPase will have FBP bound to it, and this prevents the binding of the 
Axin:LKB1 complex to the v-ATPase:Ragulator complex. Meanwhile, AMPK may already be 
partly associated with the lysosomal membrane due to the N-myristoylation of its β subunit. On 
removing glucose from the medium, aldolase now becomes unoccupied by FBP, and this causes a 
conformational change that is transmitted to the v-ATPase, causing the Axin:LKB1 complex to 
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bind to the v-ATPase:Ragulator complex and to recruit AMPK into the super-complex. This in turn 
leads to the phosphorylation and activation of AMPK by LKB1. We presume that the activated 
AMPK then dissociates from the lysosome to perform many of its downstream functions, although 
that has not yet been directly demonstrated. 
5.4 Why FBP, why aldolase and why lysosomes? 
When glucose enters cells, there is a choice between its metabolism by glycolysis, which in most 
cells is primarily a catabolic pathway that generates ATP, or by anabolic pathways such as the 
pentose phosphate pathway or glycogen synthesis (Fig. 2). FBP is the product of the enzyme 
phosphofructokinase, which catalyzes the first irreversible step in the glycolysis pathway. Once 
FBP has been reached, its fate is therefore largely committed to catabolism. This makes FBP a good 
signal that there is sufficient glucose available for catabolic purposes, so that it is not necessary for 
AMPK to switch on alternative catabolic pathways. 
 Note that this is not the only use of FBP as a signal, because some isoforms of pyruvate kinase, 
which catalyze the final step in glycolysis (Fig. 2), are subject to allosteric activation by FBP. Some 
flux downstream of aldolase can in fact be used for anabolic rather than catabolic purposes, since 3-
phosphoglycerate (3PG) is the starting point for the synthesis of the amino acids serine and glycine, 
which are required not only for protein synthesis but also for nucleotide synthesis (Fig. 2). 
Activation of pyruvate kinase by FBP would ensure that when glucose is readily available most of 
the flux would go through glycolysis to pyruvate, thus generating ATP. However, if glucose (and 
hence FBP) were in short supply a larger proportion of the flux might be diverted into the 
serine/glycine biosynthesis pathway. 
 Aldolase may be a good sensor to indicate availability of FBP, because the maximum 
concentration of FBP in cells incubated with high glucose is around 10 µM [69], but higher 
concentrations are required to saturate binding of FBP to aldolase. Thus as FBP concentration 
varies across its physiological range, the amount bound to aldolase will increase proportionately. 
 One can only speculate as to why glucose sensing by AMPK should take place on the lysosome, 
but one interesting point is that many present day protists, such as amoebae, feed primarily by 
phagocytosis, i.e. the engulfment of extracellular particles by pinching off of membrane-bound 
vesicles (phagosomes) into the cytoplasm, which are then delivered to lysosomes for digestion of 
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their contents. All eukaryotic cells also recycle their own surplus contents by autophagy, in which 
regions of the cytoplasm, including organelles, are engulfed within membrane vesicles 
(autophagosomes) that are then delivered to lysosomes for digestion (see Section 6.2). The 
lysosome can therefore be viewed as the “gut” or digestive system of the single cell, where nutrients 
like glucose, fatty acids and amino acids are generated by digestion of polysaccharides, lipids and 
proteins. It is therefore seems logical that these nutrients might be sensed there. 
5.5 Interplay between the AMPK and target-of-rapamycin pathways 
One intriguing facet of the recent findings of a role for the Ragulator complex and lysosomal 
membranes in glucose-sensing by AMPK is the close links with the mechanistic target-of-
rapamycin complex-1 (mTORC1) pathway, another ancient nutrient-sensing pathway that appears to 
be present in almost all eukaryotes. Rapamycin is an antibiotic originally isolated from a soil 
bacterium collected on the remote Pacific outcrop of Easter Island, which is known to the locals as 
Rapa Nui [81]. The target-of-rapamycin (TOR) was discovered as two related genes in brewer’s 
yeast in which loss-of-function mutations prevented the growth inhibitory effects of rapamycin 
[82]. These genes were sequenced in 1993 and shown the following year to be closely related to a 
mammalian protein (originally called RAFT1, now mTOR) that binds to a complex between 
rapamycin and a cellular binding protein called FKBP12 [83]. 
 mTOR, which in humans is encoded by a single gene, is now known to exist as two multisubunit 
complexes, i.e. mTORC1 containing mTOR and Raptor, and mTORC2 containing mTOR and 
Rictor, with both complexes also containing additional components. Although closely related to 
kinases that attach phosphate groups to lipids, mTORC1 and mTORC2 are in fact protein kinases. 
In most respects, mTORC1 acts in the opposite direction to AMPK, in that it is activated by the 
availability of nutrients, especially amino acids, and by phosphorylating downstream targets distinct 
from AMPK promotes anabolic pathways, especially the synthesis of proteins required for rapid 
cell growth [84]. It is therefore intriguing that the Ragulator complex, which is involved in the 
activation of AMPK by glucose starvation, is also involved in the activation of mTORC1 by amino 
acids. When stimulated by amino acids, by mechanisms that are still being elucidated [84], the 
Ragulator complex acts as a guanine-nucleotide exchange factor (GEF) for RagA or RagB, 
converting them to their active GTP-bound forms. RagA/B are alternative components of a 
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heterodimeric G protein that also contains RagC or RagD; when RagA/B have bound GTP, and 
RagC/D have bound GDP, mTORC1 is recruited to the lysosome via binding of Raptor to the Rag 
heterodimer [85]. However, to be fully active mTORC1 requires another lysosomal G protein, 
Rheb, to be in its GTP-bound form. This occurs when the TSC complex, which carries a GTPase-
activator protein (GAP) activity for Rheb, has dissociated from the lysosome following its 
phosphorylation by protein kinases acting downstream of growth factors [86]. Thus, mTORC1 is 
analogous to an electronic coincidence circuit in that it requires two conditions to be met before it 
becomes active: (i) amino acids are available; (ii) growth factors are present. A third condition for 
mTORC1 to be active, and thus for cell growth to be permitted, is that AMPK should be inactive, 
because AMPK inactivates mTORC1 by dual mechanisms: (i) it phosphorylates the TSC complex 
at distinct sites that oppose the effects of the protein kinases downstream of growth factors, thus 
inactivating Rheb [87]; (ii) it phosphorylates Raptor at two sites [88].  Although in both cases this 
leads to inactivation of mTORC1 in intact cells, in neither case are the effects of phosphorylation 
well understood at the molecular level.  
6. Downstream effects of AMPK, and its potential as a drug target 
6.1 Recognition of downstream targets by AMPK 
Although the majority of protein kinases, like AMPK, are specific for serine or threonine residues, 
the average protein will contain tens or even hundreds of these, while usually only one or two, or 
often none at all, are phosphorylated on a particular protein. Like some other protein kinases, 
AMPK achieves the remarkable feat of recognizing a few hundred specific serine and threonine 
residues, out of perhaps up to a million in a typical cell, because it recognizes the pattern of 
surrounding amino acids. AMPK has been shown to recognize sequences of the type β-Φ-(β,X)-X-
X-S/T-X-X-X-Φ, where β is an amino acid with a basic, positively charged side chain (arginine, 
lysine or histidine), Φ is an amino acid with a bulky hydrophobic side chain (methionine, leucine, 
isoleucine, phenylalanine or valine), X is any amino acid, S/T is the serine or threonine 
phosphorylated, and (β,X) indicated that the basic side chain (β) can be at either of the two 
positions [41, 88, 89]. This sequence motif is recognized by complementary amino acids in the 
catalytic region of AMPK, which was established by modelling the binding of the sequence around 
serine-79 on the classical downstream target, acetyl-CoA carboxylase (ACC1), to the kinase 
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domain of AMPK (Fig. 8) [41]. These complementary amino acids are mostly not contiguous 
within the amino acid sequence of AMPK, but are brought together by the way it folds up. 
Although the structures shown in Fig. 8 were the result of modelling (based on structures of closely 
related kinases) rather than actual structural analysis, the model was confirmed by mutating 
individual residues involved in binding, both on the kinase and on the target [41]. 
 The development of phosphorylation sites for a particular kinase such as AMPK on many 
different proteins is a good example of convergent evolution, in which the selection of random 
mutations cause sequences of proteins that are not closely related by their ancestry to become more 
similar, at least over short stretches. The AMPK recognition motif occurs with too high a frequency 
in protein sequences predicted by the human genome to be particularly useful in identifying new 
target proteins, but where a target protein has been identified by other means, it has been very 
useful in identifying the exact site(s) of phosphorylation. 
6.2 AMPK activation causes a metabolic switch from anabolism to catabolism 
We now know of at least 60 target proteins for AMPK, most of which are phosphorylated on just 
one or two serine/threonine residues [90]; it is anticipated that the list will eventually run into 
hundreds. Many of the early downstream targets to be discovered were metabolic enzymes: in 
general, AMPK switches on catabolic enzymes involved in the generation of ATP, while switching 
off anabolic enzymes involved in the ATP-consuming processes of synthesis and storage of 
macromolecules (Fig. 9). Thus, while slowing cell growth AMPK at the same time helps to restore 
energy balance in cells in which energy status has been compromised. 
 Since AMPK is activated by depletion of glucose as well as cellular energy, it makes sense for it 
to accelerate the use of any remaining glucose by enhancing its uptake into cells by the glucose 
transporters GLUT1 [91] and GLUT4 [92]. At the same time, AMPK promotes the initial 
metabolism of glucose (glycolysis) in some cell types by phosphorylating and activating the 
PFKFB2 and PFKFB3 isoforms of the enzyme that converts fructose-6-phosphate to fructose-2,6-
bisphosphate (F26BP), an allosteric activator of the key phosphofructokinase step in glycolysis [93, 
94]. However, as glucose runs low it also makes sense for cells to switch to the use of alternate 
fuels such as fatty acids. Thus, AMPK promotes uptake of fatty acids into cells via the fatty acid 
transporter CD36 [95], while also phosphorylating and inactivating acetyl-CoA carboxylase (ACC) 
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that synthesizes malonyl-CoA, an inhibitor of fatty acid uptake into mitochondria [96]. Thus, 
AMPK activation promotes ATP synthesis by increasing both uptake and oxidation of fatty acids. 
As well as these rapid effects, in the longer term AMPK promotes fatty acid oxidation by enhancing 
the expression of oxidative enzymes within mitochondria, including enzymes that catalyse the 
Krebs or TCA cycle (the prominent cycle of reactions within mitochondria shown in Fig. 2, first 
defined by Hans Krebs) [97]. AMPK also enhances mitochondrial biogenesis [98], i.e. the synthesis 
of new mitochondrial components, by activating or stabilizing PGC-1α [99, 100], a transcriptional 
activator that enhances expression of many mitochondrial proteins, as well as the replication of 
mitochondrial DNA [101]. This ensures that AMPK promotes ATP production not only from fatty 
acids and any pyruvate derived from glycolysis, but also from amino acids such as glutamine, 
which feeds into the Krebs cycle by the pathway of glutaminolysis (Fig. 2). Glutamine is generated 
not only by breakdown of dietary proteins, but also by breakdown of muscle proteins during periods 
of prolonged starvation, and is usually the most abundant amino acid in the bloodstream. 
 A final catabolic action of AMPK, brought about by phosphorylation of the protein kinases 
ULK1/ULK2 [102],  is to promote autophagy (literally self-eating), a process in which cells engulf 
within intracellular membranes some of their own cytoplasmic proteins and organelles that are 
surplus to requirements. The resulting membrane-bound vesicles (autophagosomes) deliver their 
contents to lysosomes, where they are degraded and their components (such as glucose and amino 
acids) recycled, either for catabolism or for re-use. In cells starved of nutrients, activation of 
autophagy by AMPK increases the chances of survival via this form of self-cannibalism. On the 
other hand, damaged segments of mitochondria are also engulfed and degraded by the special form 
of autophagy known as mitophagy, even in unstarved cells. Use of molecular oxygen for 
mitochondrial metabolism comes at a price, in that by-products known as reactive oxygen species, 
especially superoxide (•O2-), hydrogen peroxide (H2O2) and hydroxyl free radicals (•OH), are 
generated. Mitochondrial proteins, lipids and DNA are particularly susceptible to damage by these 
highly reactive chemicals. Remarkably, cells seem to be able to segregate off damaged regions of 
mitochondria by the process of mitochondrial fission, in which segments of mitochondrial tubules 
are pinched off [103]. These are then delivered to autophagosomes so that their components can be 
recycled. AMPK activation, which occurs in cells that are short of either glucose or ATP, promotes 
not only mitochondrial fission by phosphorylating mitochondrial fission factor (MFF) [104] but 
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also mitophagy itself [102]. Consistent with this, cells lacking AMPK tend to accumulate abnormal 
or dysfunctional mitochondria [105, 106]. Thus, AMPK helps to maintain the entire life cycle of 
mitochondria, not only promoting production of new mitochondrial components (mitochondrial 
biogenesis) but also by disposing of old, damaged mitochondria by mitochondrial fission and 
mitophagy. This is consistent with the idea, proposed in Section 2, that the AMPK system evolved 
as a key interface between the host cell and its bacterial endosymbiotic partners. 
 In addition to these catabolic processes that are switched on by AMPK, it switches off most 
ATP-consuming, anabolic pathways (Fig. 9). It was originally discovered for its ability to 
phosphorylate and inactivate acetyl-CoA carboxylase (ACC) and 3-hydroxy-3-methyl-Coenzyme A 
reductase (HMGR) [107-109]. As well as producing malonyl-CoA that inhibits fatty acid oxidation 
(see above), ACC is the ATP-requiring enzyme that produces malonyl-CoA used in the synthesis of 
fatty acids. These tasks may be partly divided between two closely related isoforms of acetyl-CoA 
carboxylase, ACC1 and ACC2, both of which are inactivated by AMPK; ACC2 has been reported 
to be associated with mitochondria [110], and may produce the pool of malonyl-CoA that regulates 
fatty acid oxidation. On the other hand, HMG-CoA reductase is the key regulatory enzyme involved 
in the synthesis of cholesterol and other isoprenoids. AMPK has also been reported to inactivate 
glycerol phosphate acyl transferase (GPAT), an enzyme involved in triacylglycerol and 
phospholipid synthesis [111]. In addition to these rapid, direct effects to inhibit lipid synthesis, 
AMPK also appears to repress expression of lipogenic enzymes, in part by phosphorylation of the 
transcription factor SREBP1c [112]. Other direct targets of AMPK involved in anabolism include 
the muscle [113] and liver [114] isoforms of glycogen synthase, which are phosphorylated at 
equivalent N-terminal residues to cause inactivation of the enzyme; the need to co-localize AMPK 
with glycogen synthase may be part of the rationale underlying the presence of a carbohydrate-
binding module on the AMPK-β subunits (see Section 4.5). Finally, it has been estimated that 20% 
of total oxygen uptake (a measure of energy usage) in rapidly proliferating cells is required for the 
synthesis of proteins, and 15% for the synthesis of nucleic acids (DNA and RNA) [115].  As 
already discussed in Section 5.5, AMPK inactivates mTORC1 via phosphorylation of TSC2 and 
Raptor, thus inhibiting the initiation of synthesis of many proteins, especially those required for 
rapid cell growth [116]. In addition, AMPK acutely inhibits protein synthesis by phosphorylating 
and activating elongation factor-2 (EF2) kinase, a kinase that inhibits the elongation phase of 
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protein synthesis by phosphorylating EF2 [117]. This last mechanism would ensure that protein 
synthesis pauses whenever cells run low on energy. Turning now to nucleic acid synthesis, the most 
abundant cellular nucleic acid is ribosomal RNA (rRNA), which constitutes up to 80% of the RNA 
in most cells; ribosomes are the structures that synthesize new proteins and are mainly composed of 
rRNA. Indeed, AMPK inhibits rRNA synthesis via direct phosphorylation of the key transcription 
factor, TIF-IA [118]. AMPK therefore restrains the synthesis of all of the major components of 
growing cells, i.e. lipids, proteins and nucleic acids, thus restraining cell growth. 
6.3 Non-metabolic targets of AMPK 
Although AMPK was at one time mainly thought to regulate metabolism, it is becoming 
increasingly clear that it regulates many other energy-requiring processes, one example being cell 
division. The cell division cycle is conventionally divided into 4 phases: (i) G1 phase, a first phase 
of cell growth; (ii) S phase, when cellular DNA is duplicated; (iii) G2 phase, a second phase of cell 
growth; and (iv) M phase or mitosis, when the duplicated DNA is distributed equally between the 
two daughter cells. Once activated above a certain threshold, AMPK arrests progress through the 
cell cycle in G1 phase, in part by increasing the expression of inhibitory proteins that block the 
action of protein kinases required for progression into S phase [119, 120]. AMPK thus indirectly 
inhibits the synthesis of DNA by blocking entry into S phase, adding to its more direct effect on the 
synthesis of rRNA described in the last section. 
 Due to limitations on space, it is not possible to discuss all of the known targets of AMPK. 
However, another process that is very expensive in energy usage is the firing of action potentials, 
the electrical impulses that carry messages along the long processes called axons that emanate from 
the cell bodies of nerve cells (neurones). Remarkably, the constant rate of ATP turnover in some 
regions of the brain can be comparable with that in leg muscles during running of a marathon, and it 
has been estimated that the firing of action potentials account for between 25% and 50% of this 
energy expenditure, with the transmission of chemical signals between neurones (a downstream 
consequence of the firing of action potentials) accounting for all bar 15% of the remainder [121]. 
Having a large brain in humans is therefore very expensive in terms of energy consumption, 
requiring constant ingestion of large quantities of food to maintain it. Among the major consumers 
of energy in neurones (and indeed other cells) are the Na+/K+-ATPases, membrane transporters that 
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pump these ions across membranes against concentration gradients, driven directly by ATP 
hydrolysis. The Na+/K+-ATPase transports 3 Na+ ions out of cells in exchange for 2 K+ ions that 
enter, thus creating concentration gradients of Na+ and K+ ions (high outside and high inside 
respectively), as well as a charge gradient (negative inside). These transporters therefore create a 
large driving force for re-entry of Na+ ions into the cell, and a smaller driving force for exit of K+ 
ions. A local depolarisation of the membrane (when the charge gradient becomes less negative or 
even positive) causes firing of action potentials by triggering the opening of voltage-gated Na+ 
channels. These channels are selective for Na+ ions and open when they sense a depolarisation of 
the membrane; their presence is one of the key characteristics of excitable cells such as neurones. 
Opening of Na+ channels triggers more depolarisation and thus creates a positive feedback, 
initiating a kind of chain reaction in which the opening of voltage-gated Na+ channels in 
neighboring areas of membrane generates a wave of depolarisation that is propagated down the 
axon, carrying a message. At the site where the action potential was initially triggered, the 
depolarisation is quite rapidly reversed by the closure of the Na+ channels and the opening of 
voltage-gated K+ channels, which rapidly restore the original polarity by allowing K+ ions to flow in 
an outward direction. Some rapidly opening K+ channels are responsible for terminating individual 
action potentials, while others (e.g. the delayed rectified K+ channel, Kv2.1) open and close more 
slowly and are responsible for increasing the resting membrane potential, reducing the propensity of 
voltage-gated Na+ channels to open again and thus start another action potential. Interestingly, 
Kv2.1 is a target for AMPK, which phosphorylates its cytoplasmic, C-terminal tail, causing channel 
opening to shift to more negative membrane potentials [122]. Thus, the channel will open earlier 
upon membrane depolarisation, restraining the firing of more action potentials. In elegant 
confirmation of this model, micro-injection of active AMPK into cultured rat neurones reduced the 
frequency of action potentials induced by a current pulse, whereas an inactive mutant had no effect 
[122]. By this mechanism, AMPK has the potential to conserve energy in the central nervous 
system by reducing the rate of firing of action potentials, and may thus enhance the survival of 
neurones that are under energetic stress. Putting this rather flippantly, it could be argued that it is 
better for neurones to work slowly than not to work at all! 
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6.4 Uses of AMPK activators and inhibitors to treat human disease 
Based on the ability of AMPK to switch cell metabolism from an anabolic mode (in which 
macromolecules are synthesized and stored) to a catabolic mode (in which stored nutrients are 
broken down and their components oxidized to CO2), it was suggested in 1999 [123] that AMPK 
activation by small molecule drugs might have benefits in the treatment of metabolic disorders such 
as obesity and Type 2 diabetes. Type 2 diabetes is a disorder characterized by a high blood glucose 
that, unlike the Type 1 form, is not initially caused by lack of insulin (a hormone that promotes 
glucose uptake by muscle and inhibits glucose production by liver) but by a failure of cells to 
properly respond to insulin, the phenomenon known as insulin resistance. Although the causes of 
insulin resistance remain poorly understood, it is strongly associated with obesity, and particularly 
appears to occur when organs such as the liver and muscle store excessive quantities of nutrients, 
especially fats. 
 This prediction that AMPK activation could be used to treat Type 2 diabetes [123] was rapidly 
supported by findings that  metformin, the primary drug currently used to treat the disorder, 
activated AMPK in intact cells and in vivo [124]. Metformin was derived from an old herbal 
remedy, i.e. the plant Galega officinalis or Goat’s Rue, which was said by John Parkinson (court 
physician to James 1st of England) to be “effectual against all infections” [125]. Metformin and a 
related drug, phenformin, are synthetic biguanide derivatives of galegine (the active ingredient of 
Goat’s Rue, which proved to be too toxic for use in humans and presumably also for goats!) and 
were introduced for treatment of Type 2 diabetes in the 1950s. Phenformin was subsequently 
withdrawn because in a small number of cases it caused the life-threatening side-effect of lactic 
acidosis. However, this complication is much less frequent with metformin, which has become the 
front-line drug treatment in Type 2 diabetes. Being derived from a herbal remedy, the actual direct 
targets of metformin and phenformin were unknown until two groups reported in 2000 that they 
were inhibitors of Complex I of the mitochondrial respiratory chain [126, 127] (incidentally, this 
explains the risk of lactic acidosis since production of lactic acid, an end-product of glycolysis, 
would occur when inhibition of the respiratory chain became severe). Since these drugs would 
inhibit mitochondrial ATP production they would also activate AMPK, which was indeed 
demonstrated [124]. That this was due to increases in cellular AMP was confirmed by showing that 
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metformin did not activate AMPK in cells that expressed a mutation in the γ subunit that prevented 
binding of AMP [70]. Intriguingly, at least fifty natural products of plants, many of which have 
been used in traditional Chinese medicine, have now been shown to activate AMPK [128]. 
Although the mechanism of action of the majority of these remains unknown, several, including 
berberine [129], arctigenin [130], galegine [70] and phloretin [131], inhibit Complex I of the 
respiratory chain, like metformin and phenformin. Most of these natural products are so-called 
secondary metabolites of plants, i.e. are not required for plant growth and development under 
optimal conditions. However, like galegine, many are toxic to animals, and they may be produced 
by the plant as a chemical defense to discourage grazing by insects and other animals (including 
goats!). Complex I is a remarkable multiprotein machine that is embedded in the mitochondrial 
inner membrane and contains over 40 subunits [132], and it perhaps makes a good target for such 
defensive compounds because of its crucial role in metabolism, and because many hydrophobic 
molecules might find inhibitory binding sites within such a complex structure. The plant cells that 
produce these compounds are tolerant to them because they are usually transported to, and stored in, 
either the apoplast (the extracellular space containing the cell walls) or the vacuole, where they 
would not come into contact with the mitochondria of the plant cells themselves [133]. 
 Another interesting feature of some of these compounds (e.g. berberine, metformin, phenformin, 
galegine) is that they are cations (i.e. positively charged), which means that they would accumulate 
to higher concentrations in the cytoplasm compared with the extracellular space, and then in 
mitochondria compared with the cytoplasm, because of the membrane potentials (positive outside) 
across the cell membrane and the mitochondrial inner membrane. It has been pointed out that the 
overall concentrating effect could be as much as 1000-fold, and that if these compounds were to 
cause a severe inhibition of the respiratory chain, the mitochondrial membrane potential would fall 
and their accumulation in mitochondria would be reduced, an intriguing self-limiting mechanism 
[126]. 
 Although the mechanism by which metformin activates AMPK is now clear, the question as to 
whether AMPK is responsible for the therapeutic benefits of the drug is still being debated. Indeed 
AMPK appears not to be responsible for the short-term effects of metformin to reduce liver glucose 
output [134], which may be due instead to the inhibition of one of the key enzymes of 
gluconeogenesis, fructose-1,6-bisphosphatase, by increases in the AMP:ATP ratio (see Section 1). 
	   32	  
However, through its ability to reduce fat storage, AMPK does appear to be responsible for the 
effects of metformin to reverse liver insulin resistance, thus enhancing the ability of insulin to 
repress liver glucose output in the longer term [135]. 
 As discussed above, Type 2 diabetes is due to a partial failure of insulin not only to repress 
glucose production by the liver, but also to promote glucose uptake by muscle. AMPK activation 
activates muscle glucose uptake by promoting translocation of the glucose transporter GLUT4 to 
the cell membrane [92], but metformin does not appear to taken up by muscle and therefore does 
not significantly activate AMPK in that tissue. Drugs that activate muscle AMPK might therefore 
have benefits over and above those of metformin. As discussed in Section 4.5, AMPK contains a 
unique binding site for allosteric activators called the ADaM site. Several pharmaceutical and 
biotechnology companies have carried out high-throughput screens and identified potent allosteric 
activators of AMPK that bind this site. Many are selective activators of AMPK complexes 
containing the β1 isoform and these do not activate AMPK in muscle, which primarily expresses 
the β2 isoform [136]. However, two companies have recently reported on the development of “pan-
β” activators that activate AMPK complexes containing either β isoform, and these have been 
found to be effective in lowering blood glucose in both rodent and non-human primate models of 
Type 2 diabetes [136, 137]. As yet, these have not been tested in humans, but due to their actions 
primarily being on the muscle it would be expected that their effects should be additive with those 
of metformin. 
 As discussed in Section 4.5, AMPK is also activated by binding of salicylate to the ADaM site 
[48]. Salicylate can be taken orally in the form of acetyl salicylate (aspirin) or salsalate (a dimeric 
salicylate ester) both of which are rapidly broken down to salicylate when they enter the 
bloodstream. Interestingly, in human clinical trials to treat obese individuals who were in a pre-
diabetic state (i.e. with elevated blood glucose but below the threshold to be classified as diabetic), 
salsalate was found to be more effective in lowering blood glucose than placebo [138]. Although it 
was proposed that this effect was due to inhibition of another signalling pathway, the concentrations 
of salicylate measured in the bloodstream should have been sufficient to cause activation of AMPK 
[48], and this may have contributed to the glucose-lowering effect. 
 The discovery that LKB1 was the principal upstream kinase phosphorylating Thr172 on AMPK 
[30-32] was exciting, because LKB1 had been previously identified as a tumour suppressor, i.e. a 
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protein that restrains cell division and hence cancer [139]. Since AMPK activation inhibits cell 
growth and division (see Sections 6.2 and 6.3) it seems possible that AMPK exerts some of the 
tumour suppressor effects of LKB1. There is indeed evidence, based on a mouse model of B cell 
lymphoma, that AMPK exerts tumour suppressor effects by switching metabolism from the 
glycolytic mode typical of many tumour cells to the more oxidative mode typical of quiescent cells 
[140]. However, the role of AMPK in cancer is complex. In proliferative disorders of blood cells, 
such as leukaemias and lymphomas, it is perhaps less likely that the cells will become starved of 
nutrients or oxygen, and AMPK may indeed suppress growth of the cancer cells and have anti-
cancer effects. However, in solid tumours, where tumours may grow so rapidly that they exceed the 
capacity of existing blood vessels to supply them with oxygen and nutrients, AMPK may 
paradoxically aid survival of cells that are under nutrient stress and, as discussed in Section 4.6, 
may even improve their blood supply by promoting angiogenesis. Consistent with this, genes 
encoding the α1 and β2 isoforms of AMPK are frequently amplified together in cancers, especially 
in adenocarcinoma of the lung (the commonest form of lung cancer), where the frequency may be 
as high as 10-15% of cases [27, 141]. Our current hypothesis is that, by restraining cell growth and 
division, over-expression of AMPK may limit growth and thus aid survival of the cells until an 
improved blood supply has been established by angiogenesis. In such cases, inhibitors of AMPK 
might provide therapeutic benefits by enhancing the effectiveness of existing chemotherapeutic 
agents. 
7. Conclusions 
AMPK is expressed universally in all eukaryotes, with the notable exception of certain parasites 
that mainly reproduce inside other eukaryotic cells, which may have been able to dispense with 
AMPK because their host cell would provide it. The classical or canonical role of the AMPK 
system is as a sensor of cellular energy status, and we speculate that it may have evolved quite soon 
after the endosymbiotic acquisition of aerobic bacteria into an archaeal host cell, which many 
people believe is the critical event that led to the development of the first eukaryote. Since in 
modern day organisms AMPK promotes mitochondrial biogenesis when it detects that the primary 
output of the organelle, ATP, is insufficient to meet demand, it is interesting to speculate that 
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AMPK evolved to provide the key interface between the host cell and its newly acquired 
endosymbiont. 
 The AMPK heterotrimer is a complex multiprotein machine that converts changes in cellular 
adenine nucleotides into changes in protein kinase activity. Structural analysis is slowly revealing 
how AMPK succeeds in the difficult task of detecting small changes in AMP despite the presence 
of much higher concentrations of ATP. 
 Genetic evidence from fungi and plants suggests that one of the primary roles of AMPK is in 
glucose-sensing, and recent evidence suggests that mammalian AMPK can also sense declining 
glucose supply by a non-canonical mechanism that is independent of changes in AMP and ATP. 
Glucose sensing occurs via a complex mechanism involving the Ragulator complex and the v-
ATPase at the lysosomal surface. Lack of glucose causes a drop in the binding of fructose-1,6-
bisphosphate to the glycolytic enzyme aldolase, which is known to bind to the v-ATPase. This 
triggers the binding of the Axin:LKB1 complex to the v-ATPase and the Ragulator, triggering 
phosphorylation and activation of AMPK, which may already be partly located at the lysosomal 
membrane due to N-myristoylation of the β subunit. Elucidation of this mechanism has revealed the 
close links between the regulation of AMPK and mTORC1, another nutrient-sensing pathway that 
appears to have arisen very early during eukaryotic evolution. 
 AMPK achieves the difficult task of recognizing and phosphorylating perhaps a few hundred 
target serine/threonine residues, out of perhaps around a million in a typical cell, by recognising the 
pattern of amino acids around the target. In the context of its role as an energy sensor, AMPK acts 
to restore energy homeostasis by switching on catabolic pathways that generate ATP, while 
switching off energy-consuming processes such as cell growth and division, and the firing of action 
potentials in neurones. In the context of its role as a glucose sensor, AMPK switches on catabolic 
pathways that utilize alternate carbon sources, such as fatty acids or glutamine. The AMPK system 
is a prime target for the development of novel drugs aimed at treatment of metabolic disorders such 
as obesity and Type 2 diabetes, as well as cancer. 
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FIGURE LEGENDS 
Figure 1: Reactions catalyzed by (A) ATPases or ATP synthases; and (B) adenylate 
kinases. 
Figure 2:  Schematic diagram of the major catabolic pathways (and selected anabolic 
pathways) in a typical animal cell, showing how they are distributed between the 
cytoplasm and the mitochondria. Key to intermediates: G6P, glucose-6-phosphate; 
G1P, glucose-1-phosphate; UDPG, UDP-glucose; F6P, fructose-6-phosphate; FBP, 
fructose-1,6-bisphosphate; triose-P, dihydroxyacetone phosphate or glyceraldehyde-3-
phosphate; 3PG, 3-phosphoglycerate; 2PG, 2-phosphoglycerate, PEP, 
phosphoenolpyruvate; 2OG, 2-oxoglutarate; OAA, oxaloacetate. 
Figure 3: (A) Transmission electron micrograph; and (B) fluorescence micrograph of cells 
showing mitochondria. The image of a human lung cell in (A) (placed in the public 
domain by Louisa Howard) reveals the double membrane surrounding mitochondria, 
and the invaginations of the inner membrane known as cristae. The fluorescence 
micrograph in (B) (by Simon Troeder, CC BY 4.0), which is at much lower 
magnification, shows mitochondria in two human cells expressing a mitochondrially 
targeted green fluorescent protein, and reveals that mitochondria actually form a 
branching network of tubules. The image in (A) is of two tubules sampled as thin 
sections, which therefore appear to be spherical or ovoid. 
Figure 4: The distinct reactions catalyzed by protein kinases and protein phosphatases. 
Figure 5: Tripartite mechanism for activation of AMPK by increases in the cellular 
AMP:ATP ratio, and by the non-canonical Ca2+-CaMKK pathway. Binding of 
AMP to the AMPK-γ subunit causes activation by: (1) promoting phosphorylation by 
LKB1; (2) inhibiting dephosphorylation by protein phosphatases; and (3) allosteric 
activation. Binding of ADP at higher concentration can mimic effect (2), whereas 
bnding of ATP antagonizes all three effects. Increases in intracellular Ca2+ activate 
CaMKK2, which phosphorylates the same site on AMPK (Thr172) as LKB1. 
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Figure 6: Schematic depiction of changes in domain disposition in the AMPK heterotrimer 
when AMP (top) rather than ATP (bottom) is bound to the CBS3 site on the γ  
subunit. The model at the top is based on the structure of the human α1β2γ1 complex, 
crystallized with Thr172 phosphorylated in the presence of AMP and cyclodextrin 
(PDB file 4RER) [39]; the two views are rotated by 70o with respect to each other 
around the y axis. The model at the bottom (of the same two views) is a hypothetical 
structure in which the catalytic and nucleotide binding modules have shifted apart 
upon displacement of AMP by ATP, with consequent release of the α-linker from the 
CBS3 site. 
Figure 7: Model for the non-canonical, AMP-independent activation of AMPK upon 
glucose starvation. In the presence of glucose, a high flux through glycolysis means 
that aldolase, which associates with the v-ATPase on the lysosomal membrane, has 
fructose-1,6-bisphosphate (FBP) bound, preventing interaction of the Axin:LKB1 
complex, which is cytoplasmic, with the v-ATPase and the Ragulator. AMPK may 
already be at least partly located on the lysosome due to N-myristoylation of the β 
subunit. On removal of glucose, aldolase is now largely unoccupied by FBP and a 
conformational change allows the Axin:LKB1 complex to bind to the v-ATPase and 
the Ragulator. LKB1 now phosphorylates and activates AMPK: whether this causes 
dissociation of the active AMPK from the lysosomal membrane remains unclear at 
present. Diagram courtesy of Chensong Zhang and Shengcai Lin, based on [69]. 
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Figure 8: AMPK recognizes its targets by means of complementary interactions between 
amino acid side chains surrounding the target serine/threonine residues and side 
chains from the kinase domain of AMPK. The images were based on a model of the 
kinase domain with the sequence around Ser79 on the downstream target aectyl-CoA 
carboxylase (ACC) bound to it [41]. The kinase domain is in “spacefilling” 
representation, while the ACC sequence is in “cartoon” representation with the 
polypeptide backbone represented as a narrow green ribbon, and specific side chains 
shown with carbon atoms in green, nitrogen in blue, and sulphur in orange. (A) The 
basic side chain (Arg75) at P-4 (i.e. 4 residues N-terminal to the target serine) binds to 
an acidic patch (red) formed by Asp103 and Glu100 from the kinase domain, while the 
hydrophobic side chain at P-5 (Met74) interacts with a hydrophobic pocket (orange) 
containing Leu212 from the kinase domain; (B) the basic side chain (His73) at P-6 
interacts with an acidic patch (red) formed by Asp215, Asp216 and Asp217; (C) the 
basic side chain at P+3 (His82) interacts with Asp56 from the kinase domain, while 
the hydrophobic side chains at P+4 (Leu 83) interacts with a hydrophobic pocket 
(orange) on the surface of the α-KD; (D) the α-helix running from P-16 to P-5 binds 
in a hydrophobic groove (the target protein-binding groove, see Fig. 6), with the 
hydrophobic side chains of Ile63 (P-16), Leu66 (P-13), Leu70 (P-9) and Met74 (P-5) 
binding in the groove. 
Figure 9: Summary of catabolic pathways (green) switched on and anabolic pathways (red) 
switched off when AMPK is activated. Green arrows indicate activation and red 
lines with bars across the end indicate inhibition. Key to acronyms: GLUT1/GLUT4, 
glucose transporter-1/-4; F26BP, fructose-2,6-bisphosphate; CD36, cluster of 
differention 36, a fatty acid transporter; ACC1/ACC2, acetyl-CoA carboxylase-1/-2; 
PGC1α, peroxisome proliferator-activated receptor co-activator-1α; ULK1/2, UNC-
51-like kinase-1/-2; MFF, mitochondrial fission factor; HMGR, HMG-CoA reductase; 
GPAT, glycerol phosphate acyltransferase; SREBP1c, sterol response element-binding 
protein-1c; TSC2, tuberous sclerosis complex protein-2; EF2, elongation factor-2; 
TIF-IA, transcription initiation factor-IA. 
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